Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 4/2015

Open Access 01-04-2015 | Research Article

Gene and protein expression of glucose transporter 1 and glucose transporter 3 in human laryngeal cancer—the relationship with regulatory hypoxia-inducible factor-1α expression, tumor invasiveness, and patient prognosis

Authors: Katarzyna Starska, Ewa Forma, Paweł Jóźwiak, Magdalena Bryś, Iwona Lewy-Trenda, Ewa Brzezińska-Błaszczyk, Anna Krześlak

Published in: Tumor Biology | Issue 4/2015

Login to get access

Abstract

Increased glucose uptake mediated by glucose transporters and reliance on glycolysis are common features of malignant cells. Hypoxia-inducible factor-1α supports the adaptation of hypoxic cells by inducing genes related to glucose metabolism. The contribution of glucose transporter (GLUT) and hypoxia-inducible factor-1α (HIF-1α) activity to tumor behavior and their prognostic value in head and neck cancers remains unclear. The aim of this study was to examine the predictive value of GLUT1, GLUT3, and HIF-1α messenger RNA (mRNA)/protein expression as markers of tumor aggressiveness and prognosis in laryngeal cancer. The level of hypoxia/metabolic marker genes was determined in 106 squamous cell laryngeal cancer (SCC) and 73 noncancerous matched mucosa (NCM) controls using quantitative real-time PCR. The related protein levels were analyzed by Western blot. Positive expression of SLC2A1, SLC2A3, and HIF-1α genes was noted in 83.9, 82.1, and 71.7 % of SCC specimens and in 34.4, 59.4, and 62.5 % of laryngeal cancer samples. Higher levels of mRNA/protein for GLUT1 and HIF-1α were noted in SCC compared to NCM (p < 0.05). SLC2A1 was found to have a positive relationship with grade, tumor front grading (TFG) score, and depth and mode of invasion (p < 0.05). SLC2A3 was related to grade and invasion type (p < 0.05). There were also relationships of HIF-1α with pTNM, TFG scale, invasion depth and mode, tumor recurrences, and overall survival (p < 0.05). In addition, more advanced tumors were found to be more likely to demonstrate positive expression of these proteins. In conclusion, the hypoxia/metabolic markers studied could be used as molecular markers of tumor invasiveness in laryngeal cancer.
Literature
1.
2.
Kondo S, Mukudai Y, Soga D, Nishida T, Takigawa M, Shirota T. Differential expression of vascular endothelial growth factor in high- and low-metastasis cell lines of salivary gland adenoid cystic carcinoma. Anticancer Res. 2014;34:671–7.PubMed
3.
Lan L, Luo Y, Cui D, Shi BY, Deng W, Huo LL, et al. Epithelial-mesenchymal transition triggers cancer stem cell generation in human thyroid cancer cells. Int J Oncol. 2013;43:113–20.PubMed
4.
Jing SW, Wang YD, Chen LQ, Sang MX, Zheng MM, Sun GG, et al. Hypoxia suppresses E-cadherin and enhances matrix metalloproteinase-2 expression favoring esophageal carcinoma migration and invasion via hypoxia inducible factor-1 alpha activation. Dis Esophagus. 2013;26:75–83.CrossRefPubMed
5.
Eckert AW, Kappler M, Schubert J, Taubert H. Correlation of expression of hypoxia-related proteins with prognosis in oral squamous cell carcinoma patients. Oral Maxillofac Surg. 2012;16:189–96.CrossRefPubMed
6.
7.
8.
Wu XH, Chen SP, Mao JY, Ji XX, Yao HT, Zhou SH. Expression and significance of hypoxia-inducible factor-1α and glucose transporter-1 in laryngeal carcinoma. Oncol Lett. 2013;5:261–6.PubMed
9.
10.
Cui Y, Nadiminty N, Liu C, Lou W, Schwartz CT, Gao AC. Upregulation of glucose metabolism by NF-κB2/p52 mediates enzalutamide resistance in castration-resistant prostate cancer cells. Endocr Relat Cancer. 2014;21:435–42.CrossRefPubMedPubMedCentral
11.
12.
Xu YY, Bao YY, Zhou SH, Fan J. Effect on the expression of MMP-2, MT-MMP in laryngeal carcinoma Hep-2 cell line by antisense glucose transporter-1. Arch Med Res. 2012;43:395–401.CrossRefPubMed
13.
Sun XP, Dong X, Lin L, Jiang X, Wei Z, Zhai B, et al. Up-regulation of survivin by AKT and hypoxia-inducible factor 1α contributes to cisplatin resistance in gastriccancer. FEBS J. 2014;281:115–28.CrossRefPubMed
14.
15.
Chen XH, Bao YY, Zhou SH, Wang QY, Wei Y, Fan J. Glucose transporter-1 expression in CD133+ laryngeal carcinoma Hep-2 cells. Mol Med Rep. 2013;8:1695–700.PubMed
16.
Kobayashi M, Kaida H, Kawahara A, Hattori S, Kurata S, Hayakawa M, et al. The relationship between GLUT-1 and vascular endothelial growth factor expression and 18F-FDG uptake in esophageal squamous cell cancer patients. Clin Nucl Med. 2012;37:447–52.CrossRefPubMed
17.
Eckert AW, Lautner MH, Schütze A, Taubert H, Schubert J, Bilkenroth U. Coexpression of hypoxia-inducible factor-1α and glucose transporter-1 is associated with poor prognosis in oral squamous cell carcinoma patients. Histopathology. 2011;58:1136–47.CrossRefPubMed
18.
Ayala FR, Rocha RM, Carvalho KC, Carvalho AL, da Cunha IW, Lourenço SV, et al. GLUT1 and GLUT3 as potential prognostic markers for oral squamous cell carcinoma. Molecules. 2010;15:2374–87.CrossRefPubMed
19.
Demasi AP, Costa AF, Altemani A, Furuse C, Araújo NS, Araújo VC. Glucose transporter protein 1 expression in mucoepidermoid carcinoma of salivary gland: correlation with grade of malignancy. Int J Exp Pathol. 2010;91:107–13.CrossRefPubMedPubMedCentral
20.
Ohba S, Fujii H, Ito S, Fujimaki M, Matsumoto F, Furukawa M, et al. Overexpression of GLUT-1 in the invasion front is associated with depth of oral squamous cell carcinoma and prognosis. J Oral Pathol Med. 2010;39:74–8.CrossRefPubMed
21.
Ciampi R, Vivaldi A, Romei C, Del Guerra A, Salvadori P, Cosci B, et al. Expression analysis of facilitative glucose transporters (GLUTs) in human thyroid carcinoma cell lines and primary tumors. Mol Cell Endocrinol. 2008;291:57–62.CrossRefPubMed
22.
Zhou S, Wang S, Wu Q, Fan J, Wang Q. Expression of glucose transporter-1 and -3 in the head and neck carcinoma—the correlation of the expression with the biological behaviors. ORL J Otorhinolaryngol Relat Spec. 2008;70:189–94.CrossRefPubMed
23.
Kaida H, Hiromatsu Y, Kurata S, Kawahara A, Hattori S, Taira T, et al. Relationship between clinicopathological factors and fluorine-18-fluorodeoxyglucose uptake in patients with papillary thyroid cancer. Nucl Med Commun. 2011;32:690–8.CrossRefPubMed
24.
Kaida H, Ishibashi M, Yuzuriha M, Kurata S, Arikawa S, Kawahara A, et al. Glucose transporter expression of an esophageal gastrointestinal tumor detected by F-18 FDG PET/CT. Clin Nucl Med. 2010;35:505–9.CrossRefPubMed
25.
Müssig K, Wehrmann T, Dittmann H, Wehrmann M, Ueberberg B, Schulz S, et al. Expression of the proliferation marker Ki-67 associates with tumour staging and clinical outcome in differentiated thyroid carcinomas. Clin Endocrinol (Oxf). 2012;77:139–45.CrossRef
26.
Kondo Y, Yoshikawa K, Omura Y, Shinohara A, Kazaoka Y, Sano J, et al. Oncol Clinicopathological significance of carbonic anhydrase 9, glucose transporter-1, Ki-67 and p53 expression in oral squamous cell carcinoma. Oncol Rep. 2011;25:1227–33.PubMed
27.
Yan SX, Luo XM, Zhou SH, Bao YY, Fan J, Lu ZJ, et al. Effect of antisense oligodeoxynucleotides glucose transporter-1 on enhancement of radiosensitivity of laryngeal carcinoma. Int J Med Sci. 2013;10:1375–86.CrossRefPubMedPubMedCentral
28.
Shimanishi M, Ogi K, Sogabe Y, Kaneko T, Dehari H, Miyazaki A, et al. Silencing of GLUT-1 inhibits sensitization of oral cancer cells to cisplatin during hypoxia. J Oral Pathol Med. 2013;42:382–8.CrossRefPubMed
29.
Ping W, Sun W, Zu Y, Chen W, Fu X. Clinicopathological and prognostic significance of hypoxia-inducible factor-1α in esophageal squamous cell carcinoma: a meta-analysis. Tumour Biol. 2014;35:4401–9.CrossRefPubMed
30.
Koperek O, Akin E, Asari R, Niederle B, Neuhold N. Expression of hypoxia-inducible factor 1 alpha in papillary thyroid carcinoma is associated with desmoplastic stromal reaction and lymph node metastasis. Virchows Arch. 2013;463:795–802.CrossRefPubMed
31.
Li DW, Zhou L, Jin B, Xie J, Dong P. Expression and significance of hypoxia-inducible factor-1α and survivin in laryngeal carcinoma tissue and cells. Otolaryngol Head Neck Surg. 2013;148:75–81.CrossRefPubMed
32.
Douglas CM, Bernstein JM, Ormston VE, Hall RC, Merve A, Swindell R, et al. Lack of prognostic effect of carbonic anhydrase-9, hypoxia inducible factor-1α and bcl-2 in 286 patients with early squamous cell carcinoma of the glottic larynx treated with radiotherapy. Clin Oncol (R Coll Radiol). 2013;25:59–65.CrossRef
33.
Cabanillas R, Rodrigo JP, Secades P, Astudillo A, Nieto CS, Chiara MD. The relation between hypoxia-inducible factor (HIF)-1alpha expression with p53 expression and outcome in surgically treated supraglottic laryngeal cancer. J Surg Oncol. 2009;99:373–8.CrossRefPubMed
34.
Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471–4.CrossRefPubMed
35.
Starska K, Kulig A, Lukomski M. Tumor front grading in prediction of survival and lymph node metastases in patients with laryngeal carcinoma. Adv Med Sci. 2006;51:200–4.PubMed
36.
Cadman E, Bostwick JR, Eichberg J. Determination of protein by a modified Lowry procedure in the presence of some commonly used detergents. Anal Biochem. 1979;96:21–3.CrossRefPubMed
37.
Kwon OJ, Park JJ, Ko GH, Seo JH, Jeong BK, Kang KM, et al. HIF-1α and CA-IX as predictors of locoregional control for determining the optimal treatment modality for early-stage laryngeal carcinoma. Head Neck. 2014. doi:10.​1002/​hed.​23620.
38.
Burstein DE, Nagi C, Kohtz DS, Lumerman H, Wang BY. Immunohistochemical detection of GLUT1, p63 and phosphorylated histone H1 in head and neck squamous intraepithelial neoplasia: evidence for aberrations in hypoxia-related, cell cycle- and stem-cell-regulatory pathways. Histopathology. 2006;48:708–16.CrossRefPubMed
39.
Zhang X, Han S, Han HY, Ryu MH, Kim KY, Choi EJ, et al. Risk prediction for malignant conversion of oral epithelial dysplasia by hypoxia related protein expression. Pathology. 2013;45:478–83.CrossRefPubMed
40.
Xie J, Li DW, Chen XW, Wang F, Dong P. Expression and significance of hypoxia-inducible factor-1α and MDR1/P-glycoprotein in laryngeal carcinoma tissue and hypoxic Hep-2 cells. Oncol Lett. 2013;6:232–8.PubMedPubMedCentral
41.
Fenske W, Völker HU, Adam P, Hahner S, Johanssen S, Wortmann S, et al. Glucose transporter GLUT1 expression is an stage-independent predictor of clinical outcome in adrenocortical carcinoma. Endocr Relat Cancer. 2009;16:919–28.CrossRefPubMed
42.
43.
Roh JL, Cho KJ, Kwon GY, Ryu CH, Chang HW, Choi SH, et al. The prognostic value of hypoxia markers in T2-staged oral tongue cancer. Oral Oncol. 2009;45:63–8.CrossRefPubMed
44.
Schrijvers ML, van der Laan BF, de Bock GH, Pattje WJ, Mastik MF, Menkema L, et al. Overexpression of intrinsic hypoxia markers HIF1alpha and CA-IX predict for local recurrence in stage T1-T2 glottic laryngeal carcinoma treated with radiotherapy. Int J Radiat Oncol Biol Phys. 2008;72:161–9.CrossRefPubMed
45.
Yamada T, Uchida M, Kwang-Lee K, Kitamura N, Yoshimura T, Sasabe E, et al. Correlation of metabolism/hypoxia markers and fluorodeoxyglucose uptake in oral squamous cell carcinomas. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012;113:464–71.CrossRefPubMed
Metadata
Title
Gene and protein expression of glucose transporter 1 and glucose transporter 3 in human laryngeal cancer—the relationship with regulatory hypoxia-inducible factor-1α expression, tumor invasiveness, and patient prognosis
Authors
Katarzyna Starska
Ewa Forma
Paweł Jóźwiak
Magdalena Bryś
Iwona Lewy-Trenda
Ewa Brzezińska-Błaszczyk
Anna Krześlak
Publication date
01-04-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 4/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2838-4

Other articles of this Issue 4/2015

Tumor Biology 4/2015 Go to the issue

Research Article

Serum adiponectin levels may be associated with the pathogenesis of hepatocellular carcinoma

Research Article

SMYD3 overexpression was a risk factor in the biological behavior and prognosis of gastric carcinoma

Review

Role of Yes-associated protein 1 in gliomas: pathologic and therapeutic aspects

Research Article

Gli-1 is crucial for hypoxia-induced epithelial-mesenchymal transition and invasion of breast cancer

Research Article

p53 suppresses CCL2-induced subcutaneous tumor xenograft

Research Article

TFF3 and HER2 expression and their correlation with survival in gastric cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits